2 hours ago
1
Justin Sullivan/Getty Images News
Gilead Sciences (NASDAQ:GILD) announced on Tuesday that the European Commission granted marketing authorization for its antiviral therapy lenacapavir as a twice-yearly option for the prevention of HIV in pre-exposure prophylaxis (PrEP).
Accordingly, the HIV-1 capsid inhibitor will be available across the
English (US) ·